img

Global Anti-Diabetic Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Diabetic Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
Due to the COVID-19 pandemic, the global Anti-Diabetic Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Biguanides accounting for % of the Anti-Diabetic Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Type I Diabetes segment is altered to an % CAGR throughout this forecast period.
Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II. 
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Anti-Diabetic Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Anti-Diabetic Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Anti-Diabetic Drugs market. Readers of the report can become informed about current and future trends of the global Anti-Diabetic Drugs market and how they will impact market growth during the forecast period.



By Company


Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Segment by Type
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors

Segment by Application


Type I Diabetes
Type II Diabetes
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Anti-Diabetic Drugs in global and regional level.
Chapter 3Detailed analysis of Anti-Diabetic Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Diabetic Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Diabetic Drugs Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Biguanides
1.2.3 Sulfonylureas
1.2.4 Meglitinides
1.2.5 Thiazolidinediones
1.2.6 Dipeptidyl Peptidase IV Inhibitors
1.2.7 α-Glucosidase Inhibitors
1.3 Market by Application
1.3.1 Global Anti-Diabetic Drugs Market Growth Rate by Application: 2018 VS 2024 VS 2034
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Anti-Diabetic Drugs Market Size (2018-2034)
2.2 Anti-Diabetic Drugs Market Size across Key Geographies Worldwide: 2018 VS 2024 VS 2034
2.3 Global Anti-Diabetic Drugs Market Size by Region (2018-2023)
2.4 Global Anti-Diabetic Drugs Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Anti-Diabetic Drugs Countries Ranking by Market Size
3 Anti-Diabetic Drugs Competitive by Company
3.1 Global Anti-Diabetic Drugs Revenue by Players
3.1.1 Global Anti-Diabetic Drugs Revenue by Players (2018-2023)
3.1.2 Global Anti-Diabetic Drugs Market Share by Players (2018-2023)
3.2 Global Anti-Diabetic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Anti-Diabetic Drugs Revenue
3.4 Global Anti-Diabetic Drugs Market Concentration Ratio
3.4.1 Global Anti-Diabetic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Diabetic Drugs Revenue in 2024
3.5 Global Key Players of Anti-Diabetic Drugs Head office and Area Served
3.6 Global Key Players of Anti-Diabetic Drugs, Product and Application
3.7 Global Key Players of Anti-Diabetic Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Anti-Diabetic Drugs Breakdown Data by Type
4.1 Global Anti-Diabetic Drugs Historic Revenue by Type (2018-2023)
4.2 Global Anti-Diabetic Drugs Forecasted Revenue by Type (2024-2034)
5 Global Anti-Diabetic Drugs Breakdown Data by Application
5.1 Global Anti-Diabetic Drugs Historic Market Size by Application (2018-2023)
5.2 Global Anti-Diabetic Drugs Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Anti-Diabetic Drugs Revenue by Company (2021-2023)
6.2 North America Anti-Diabetic Drugs Revenue by Type (2018-2034)
6.3 North America Anti-Diabetic Drugs Revenue by Application (2018-2034)
6.4 North America Anti-Diabetic Drugs Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Anti-Diabetic Drugs Revenue by Company (2021-2023)
7.2 Europe Anti-Diabetic Drugs Revenue by Type (2018-2034)
7.3 Europe Anti-Diabetic Drugs Revenue by Application (2018-2034)
7.4 Europe Anti-Diabetic Drugs Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Anti-Diabetic Drugs Revenue by Company (2021-2023)
8.2 Asia Pacific Anti-Diabetic Drugs Revenue by Type (2018-2034)
8.3 Asia Pacific Anti-Diabetic Drugs Revenue by Application (2018-2034)
8.4 Asia Pacific Anti-Diabetic Drugs Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Anti-Diabetic Drugs Revenue by Company (2021-2023)
9.2 Latin America Anti-Diabetic Drugs Revenue by Type (2018-2034)
9.3 Latin America Anti-Diabetic Drugs Revenue by Application (2018-2034)
9.4 Latin America Anti-Diabetic Drugs Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Anti-Diabetic Drugs Revenue by Company (2021-2023)
10.2 Middle East and Africa Anti-Diabetic Drugs Revenue by Type (2018-2034)
10.3 Middle East and Africa Anti-Diabetic Drugs Revenue by Application (2018-2034)
10.4 Middle East and Africa Anti-Diabetic Drugs Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Astra Zeneca
11.1.1 Astra Zeneca Company Details
11.1.2 Astra Zeneca Business Overview
11.1.3 Astra Zeneca Anti-Diabetic Drugs Products and Services
11.1.4 Astra Zeneca Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.1.5 Astra Zeneca Anti-Diabetic Drugs SWOT Analysis
11.1.6 Astra Zeneca Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Anti-Diabetic Drugs Products and Services
11.2.4 Boehringer Ingelheim Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.2.5 Boehringer Ingelheim Anti-Diabetic Drugs SWOT Analysis
11.2.6 Boehringer Ingelheim Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Anti-Diabetic Drugs Products and Services
11.3.4 Eli Lilly Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.3.5 Eli Lilly Anti-Diabetic Drugs SWOT Analysis
11.3.6 Eli Lilly Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Anti-Diabetic Drugs Products and Services
11.4.4 Johnson & Johnson Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.4.5 Johnson & Johnson Anti-Diabetic Drugs SWOT Analysis
11.4.6 Johnson & Johnson Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Anti-Diabetic Drugs Products and Services
11.5.4 Merck Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.5.5 Merck Anti-Diabetic Drugs SWOT Analysis
11.5.6 Merck Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Anti-Diabetic Drugs Products and Services
11.6.4 Novartis Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.6.5 Novartis Anti-Diabetic Drugs SWOT Analysis
11.6.6 Novartis Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Anti-Diabetic Drugs Products and Services
11.7.4 Novo Nordisk Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.7.5 Novo Nordisk Anti-Diabetic Drugs SWOT Analysis
11.7.6 Novo Nordisk Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Anti-Diabetic Drugs Products and Services
11.8.4 Sanofi Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.8.5 Sanofi Anti-Diabetic Drugs SWOT Analysis
11.8.6 Sanofi Recent Development
11.9 Teva Pharmaceutical Industries
11.9.1 Teva Pharmaceutical Industries Company Details
11.9.2 Teva Pharmaceutical Industries Business Overview
11.9.3 Teva Pharmaceutical Industries Anti-Diabetic Drugs Products and Services
11.9.4 Teva Pharmaceutical Industries Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023)
11.9.5 Teva Pharmaceutical Industries Anti-Diabetic Drugs SWOT Analysis
11.9.6 Teva Pharmaceutical Industries Recent Development
12 Anti-Diabetic Drugs Market Dynamics
12.1 Anti-Diabetic Drugs Industry Trends
12.2 Anti-Diabetic Drugs Market Drivers
12.3 Anti-Diabetic Drugs Market Challenges
12.4 Anti-Diabetic Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Anti-Diabetic Drugs Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2024 VS 2034
Table 2. Key Players of Biguanides
Table 3. Key Players of Sulfonylureas
Table 4. Key Players of Meglitinides
Table 5. Key Players of Thiazolidinediones
Table 6. Key Players of Dipeptidyl Peptidase IV Inhibitors
Table 7. Key Players of α-Glucosidase Inhibitors
Table 8. Global Anti-Diabetic Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2024 VS 2034
Table 9. Global Anti-Diabetic Drugs Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2024 VS 2034
Table 10. Global Anti-Diabetic Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Anti-Diabetic Drugs Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 12. Global Anti-Diabetic Drugs Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Table 13. Global Anti-Diabetic Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 14. Global Anti-Diabetic Drugs Market Share by Players (2018-2023)
Table 15. Global Top Anti-Diabetic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Diabetic Drugs as of 2024)
Table 16. Ranking of Global Top Anti-Diabetic Drugs Companies by Revenue (US$ Million) in 2024
Table 17. Global 5 Largest Players Market Share by Anti-Diabetic Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 18. Global Key Players of Anti-Diabetic Drugs, Headquarters and Area Served
Table 19. Global Key Players of Anti-Diabetic Drugs, Product and Application
Table 20. Global Key Players of Anti-Diabetic Drugs, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Anti-Diabetic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 23. Global Anti-Diabetic Drugs Revenue Market Share by Type (2018-2023)
Table 24. Global Anti-Diabetic Drugs Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 25. Global Anti-Diabetic Drugs Revenue Market Share by Type (2024-2034)
Table 26. Global Anti-Diabetic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 27. Global Anti-Diabetic Drugs Revenue Market Share by Application (2018-2023)
Table 28. Global Anti-Diabetic Drugs Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 29. Global Anti-Diabetic Drugs Revenue Market Share by Application (2024-2034)
Table 30. North America Anti-Diabetic Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 31. North America Anti-Diabetic Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 32. North America Anti-Diabetic Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 33. North America Anti-Diabetic Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 34. North America Anti-Diabetic Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 35. North America Anti-Diabetic Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 36. North America Anti-Diabetic Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 37. North America Anti-Diabetic Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 38. Europe Anti-Diabetic Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 39. Europe Anti-Diabetic Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 40. Europe Anti-Diabetic Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 41. Europe Anti-Diabetic Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 42. Europe Anti-Diabetic Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 43. Europe Anti-Diabetic Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. Europe Anti-Diabetic Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 45. Europe Anti-Diabetic Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 46. Asia Pacific Anti-Diabetic Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 47. Asia Pacific Anti-Diabetic Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 48. Asia Pacific Anti-Diabetic Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 49. Asia Pacific Anti-Diabetic Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 50. Asia Pacific Anti-Diabetic Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 51. Asia-Pacific Anti-Diabetic Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 52. Asia Pacific Anti-Diabetic Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 53. Asia Pacific Anti-Diabetic Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 54. Latin America Anti-Diabetic Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 55. Latin America Anti-Diabetic Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 56. Latin America Anti-Diabetic Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 57. Latin America Anti-Diabetic Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 58. Latin America Anti-Diabetic Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 59. Latin America Anti-Diabetic Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 60. Latin America Anti-Diabetic Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 61. Latin America Anti-Diabetic Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Anti-Diabetic Drugs Revenue by Company (2021-2023) & (US$ Million)
Table 63. Middle East and Africa Anti-Diabetic Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 64. Middle East and Africa Anti-Diabetic Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Anti-Diabetic Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Anti-Diabetic Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 67. Middle East and Africa Anti-Diabetic Drugs Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 68. Middle East and Africa Anti-Diabetic Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 69. Middle East and Africa Anti-Diabetic Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 70. Astra Zeneca Company Details
Table 71. Astra Zeneca Business Overview
Table 72. Astra Zeneca Anti-Diabetic Drugs Product and Services
Table 73. Astra Zeneca Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 74. Astra Zeneca Anti-Diabetic Drugs SWOT Analysis
Table 75. Astra Zeneca Recent Development
Table 76. Boehringer Ingelheim Company Details
Table 77. Boehringer Ingelheim Business Overview
Table 78. Boehringer Ingelheim Anti-Diabetic Drugs Product and Services
Table 79. Boehringer Ingelheim Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 80. Boehringer Ingelheim Anti-Diabetic Drugs SWOT Analysis
Table 81. Boehringer Ingelheim Recent Development
Table 82. Eli Lilly Company Details
Table 83. Eli Lilly Business Overview
Table 84. Eli Lilly Anti-Diabetic Drugs Product and Services
Table 85. Eli Lilly Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 86. Eli Lilly Anti-Diabetic Drugs SWOT Analysis
Table 87. Eli Lilly Recent Development
Table 88. Johnson & Johnson Company Details
Table 89. Johnson & Johnson Business Overview
Table 90. Johnson & Johnson Anti-Diabetic Drugs Product and Services
Table 91. Johnson & Johnson Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 92. Johnson & Johnson Anti-Diabetic Drugs SWOT Analysis
Table 93. Johnson & Johnson Recent Development
Table 94. Merck Company Details
Table 95. Merck Business Overview
Table 96. Merck Anti-Diabetic Drugs Product and Services
Table 97. Merck Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 98. Merck Anti-Diabetic Drugs SWOT Analysis
Table 99. Merck Recent Development
Table 100. Novartis Company Details
Table 101. Novartis Business Overview
Table 102. Novartis Anti-Diabetic Drugs Product and Services
Table 103. Novartis Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 104. Novartis Anti-Diabetic Drugs SWOT Analysis
Table 105. Novartis Recent Development
Table 106. Novo Nordisk Company Details
Table 107. Novo Nordisk Business Overview
Table 108. Novo Nordisk Anti-Diabetic Drugs Product and Services
Table 109. Novo Nordisk Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 110. Novo Nordisk Anti-Diabetic Drugs SWOT Analysis
Table 111. Novo Nordisk Recent Development
Table 112. Sanofi Company Details
Table 113. Sanofi Business Overview
Table 114. Sanofi Anti-Diabetic Drugs Product and Services
Table 115. Sanofi Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 116. Sanofi Anti-Diabetic Drugs SWOT Analysis
Table 117. Sanofi Recent Development
Table 118. Teva Pharmaceutical Industries Company Details
Table 119. Teva Pharmaceutical Industries Business Overview
Table 120. Teva Pharmaceutical Industries Anti-Diabetic Drugs Product and Services
Table 121. Teva Pharmaceutical Industries Anti-Diabetic Drugs Revenue in Anti-Diabetic Drugs Business (2018-2023) & (US$ Million)
Table 122. Teva Pharmaceutical Industries Anti-Diabetic Drugs SWOT Analysis
Table 123. Teva Pharmaceutical Industries Recent Development
Table 124. Anti-Diabetic Drugs Market Trends
Table 125. Anti-Diabetic Drugs Market Drivers
Table 126. Anti-Diabetic Drugs Market Challenges
Table 127. Anti-Diabetic Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Diabetic Drugs Product Picture
Figure 2. Global Anti-Diabetic Drugs Market Size by Type (US$ Million): 2018 VS 2024 VS 2034
Figure 3. Global Anti-Diabetic Drugs Market Share by Type: 2024 VS 2034
Figure 4. Biguanides Features
Figure 5. Sulfonylureas Features
Figure 6. Meglitinides Features
Figure 7. Thiazolidinediones Features
Figure 8. Dipeptidyl Peptidase IV Inhibitors Features
Figure 9. α-Glucosidase Inhibitors Features
Figure 10. Global Anti-Diabetic Drugs Market Size by Application (US$ Million): 2018 VS 2024 VS 2034
Figure 11. Global Anti-Diabetic Drugs Market Share by Application: 2024 VS 2034
Figure 12. Type I Diabetes
Figure 13. Type II Diabetes
Figure 14. Others
Figure 15. Anti-Diabetic Drugs Report Years Considered
Figure 16. Global Anti-Diabetic Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Anti-Diabetic Drugs Market Size 2018-2034 (US$ Million)
Figure 18. Global Anti-Diabetic Drugs Market Size Market Share by Region: 2024 VS 2034
Figure 19. Global Anti-Diabetic Drugs Revenue Market Share by Region in 2018 VS 2024
Figure 20. Global Anti-Diabetic Drugs Revenue Market Share Forecast by Region (2024-2034)
Figure 21. Global Top 10 Anti-Diabetic Drugs Countries Ranking by Market Size (US$ Million) in 2024
Figure 22. Global Anti-Diabetic Drugs Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Figure 23. Global Anti-Diabetic Drugs Market Share by Players in 2024
Figure 24. Global Top Anti-Diabetic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Diabetic Drugs as of 2024)
Figure 25. The Top 10 and 5 Players Market Share by Anti-Diabetic Drugs Revenue in 2024
Figure 26. North America Anti-Diabetic Drugs Revenue Market Share by Company in 2024
Figure 27. North America Anti-Diabetic Drugs Revenue Market Share by Type (2018-2034)
Figure 28. North America Anti-Diabetic Drugs Revenue Market Share by Application (2018-2034)
Figure 29. North America Anti-Diabetic Drugs Revenue Share by Country (2018-2034)
Figure 30. U.S. Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 31. Canada Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 32. Europe Anti-Diabetic Drugs Revenue Market Share by Company in 2024
Figure 33. Europe Anti-Diabetic Drugs Revenue Market Share by Type (2018-2034)
Figure 34. Europe Anti-Diabetic Drugs Revenue Market Share by Application (2018-2034)
Figure 35. Europe Anti-Diabetic Drugs Revenue Share by Country (2018-2034)
Figure 36. Germany Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 37. France Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 38. U.K. Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 39. Italy Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 40. Russia Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 41. Asia Pacific Anti-Diabetic Drugs Revenue Market Share by Company in 2024
Figure 42. Asia Pacific Anti-Diabetic Drugs Revenue Market Share by Type (2018-2034)
Figure 43. Asia Pacific Anti-Diabetic Drugs Revenue Market Share by Application (2018-2034)
Figure 44. Asia Pacific Anti-Diabetic Drugs Revenue Share by Region (2018-2034)
Figure 45. China Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Japan Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. South Korea Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 48. India Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 49. Australia Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 50. Taiwan Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 51. Indonesia Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 52. Thailand Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 53. Malaysia Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 54. Philippines Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 55. Vietnam Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. Latin America Anti-Diabetic Drugs Revenue Market Share by Company in 2024
Figure 57. Latin America Anti-Diabetic Drugs Revenue Market Share by Type (2018-2034)
Figure 58. Latin America Anti-Diabetic Drugs Revenue Market Share by Application (2018-2034)
Figure 59. Latin America Anti-Diabetic Drugs Revenue Share by Country (2018-2034)
Figure 60. Mexico Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. Brazil Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 62. Argentina Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 63. Middle East and Africa Anti-Diabetic Drugs Revenue Market Share by Company in 2024
Figure 64. Middle East and Africa Anti-Diabetic Drugs Revenue Market Share by Type (2018-2034)
Figure 65. Middle East and Africa Anti-Diabetic Drugs Revenue Market Share by Application (2018-2034)
Figure 66. Middle East and Africa Anti-Diabetic Drugs Revenue Share by Country (2018-2034)
Figure 67. Turkey Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 68. Saudi Arabia Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 69. U.A.E Anti-Diabetic Drugs Revenue (2018-2034) & (US$ Million)
Figure 70. Astra Zeneca Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 71. Boehringer Ingelheim Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 72. Eli Lilly Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 73. Johnson & Johnson Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 74. Merck Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 75. Novartis Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 76. Novo Nordisk Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 77. Sanofi Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 78. Teva Pharmaceutical Industries Revenue Growth Rate in Anti-Diabetic Drugs Business (2018-2023)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed